Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. (ADMS) Stock Competitors & Peer Comparison
See (ADMS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADMS | $8.22 | +0.00% | 0 | N/A | N/A | N/A |
| TAK | $18.43 | +2.90% | 57.7B | 82.98 | $0.22 | +3.28% |
| ZTS | $117.57 | +3.72% | 51.3B | 19.33 | $6.02 | +1.75% |
| HLN | $9.96 | +1.63% | 44.7B | 20.42 | $0.49 | +1.75% |
| TEVA | $29.52 | +2.71% | 33B | 23.42 | $1.21 | N/A |
| VTRS | $13.42 | +2.80% | 14.9B | -4.32 | -$3.00 | +3.70% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $132.77 | +3.47% | 12.9B | 27.56 | $4.67 | N/A |
| ELAN | $23.92 | +3.39% | 11.7B | -49.87 | -$0.47 | N/A |
| RGC | $25.50 | -0.66% | 11.5B | -2333.00 | -$0.01 | N/A |
Stock Comparison
ADMS vs TAK Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TAK has a market cap of 57.7B. Regarding current trading prices, ADMS is priced at $8.22, while TAK trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TAK's P/E ratio is 82.98. In terms of profitability, ADMS's ROE is +2.26%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ADMS is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TAK's competition here
ADMS vs ZTS Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ZTS has a market cap of 51.3B. Regarding current trading prices, ADMS is priced at $8.22, while ZTS trades at $117.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZTS's P/E ratio is 19.33. In terms of profitability, ADMS's ROE is +2.26%, compared to ZTS's ROE of +0.58%. Regarding short-term risk, ADMS is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ZTS's competition here
ADMS vs HLN Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, HLN has a market cap of 44.7B. Regarding current trading prices, ADMS is priced at $8.22, while HLN trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HLN's P/E ratio is 20.42. In terms of profitability, ADMS's ROE is +2.26%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ADMS is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check HLN's competition here
ADMS vs TEVA Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TEVA has a market cap of 33B. Regarding current trading prices, ADMS is priced at $8.22, while TEVA trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TEVA's P/E ratio is 23.42. In terms of profitability, ADMS's ROE is +2.26%, compared to TEVA's ROE of +0.20%. Regarding short-term risk, ADMS is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TEVA's competition here
ADMS vs VTRS Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, VTRS has a market cap of 14.9B. Regarding current trading prices, ADMS is priced at $8.22, while VTRS trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas VTRS's P/E ratio is -4.32. In terms of profitability, ADMS's ROE is +2.26%, compared to VTRS's ROE of -0.23%. Regarding short-term risk, ADMS is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check VTRS's competition here
ADMS vs ITCI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ADMS is priced at $8.22, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ADMS's ROE is +2.26%, compared to ITCI's ROE of -0.04%. Regarding short-term risk, ADMS is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check ITCI's competition here
ADMS vs NBIX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, NBIX has a market cap of 12.9B. Regarding current trading prices, ADMS is priced at $8.22, while NBIX trades at $132.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 27.56. In terms of profitability, ADMS's ROE is +2.26%, compared to NBIX's ROE of +0.17%. Regarding short-term risk, ADMS is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check NBIX's competition here
ADMS vs ELAN Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ELAN has a market cap of 11.7B. Regarding current trading prices, ADMS is priced at $8.22, while ELAN trades at $23.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ELAN's P/E ratio is -49.87. In terms of profitability, ADMS's ROE is +2.26%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, ADMS is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ELAN's competition here
ADMS vs RGC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, RGC has a market cap of 11.5B. Regarding current trading prices, ADMS is priced at $8.22, while RGC trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas RGC's P/E ratio is -2333.00. In terms of profitability, ADMS's ROE is +2.26%, compared to RGC's ROE of -0.62%. Regarding short-term risk, ADMS is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check RGC's competition here
ADMS vs CTLT Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ADMS is priced at $8.22, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ADMS's ROE is +2.26%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ADMS is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check CTLT's competition here
ADMS vs RDY Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, RDY has a market cap of 11.2B. Regarding current trading prices, ADMS is priced at $8.22, while RDY trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas RDY's P/E ratio is 18.70. In terms of profitability, ADMS's ROE is +2.26%, compared to RDY's ROE of +0.16%. Regarding short-term risk, ADMS is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check RDY's competition here
ADMS vs LNTH Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, LNTH has a market cap of 4.8B. Regarding current trading prices, ADMS is priced at $8.22, while LNTH trades at $75.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LNTH's P/E ratio is 21.43. In terms of profitability, ADMS's ROE is +2.26%, compared to LNTH's ROE of +0.21%. Regarding short-term risk, ADMS is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check LNTH's competition here
ADMS vs AMRX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, AMRX has a market cap of 3.8B. Regarding current trading prices, ADMS is priced at $8.22, while AMRX trades at $12.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AMRX's P/E ratio is 54.32. In terms of profitability, ADMS's ROE is +2.26%, compared to AMRX's ROE of -0.68%. Regarding short-term risk, ADMS is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check AMRX's competition here
ADMS vs INDV Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, INDV has a market cap of 3.6B. Regarding current trading prices, ADMS is priced at $8.22, while INDV trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas INDV's P/E ratio is 17.55. In terms of profitability, ADMS's ROE is +2.26%, compared to INDV's ROE of -0.99%. Regarding short-term risk, ADMS is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check INDV's competition here
ADMS vs SUPN Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ADMS is priced at $8.22, while SUPN trades at $51.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SUPN's P/E ratio is -72.57. In terms of profitability, ADMS's ROE is +2.26%, compared to SUPN's ROE of -0.00%. Regarding short-term risk, ADMS is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SUPN's competition here
ADMS vs HCM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, ADMS is priced at $8.22, while HCM trades at $14.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HCM's P/E ratio is 5.40. In terms of profitability, ADMS's ROE is +2.26%, compared to HCM's ROE of +0.41%. Regarding short-term risk, ADMS is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check HCM's competition here
ADMS vs DCPH Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ADMS is priced at $8.22, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ADMS's ROE is +2.26%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ADMS is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check DCPH's competition here
ADMS vs PAHC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, PAHC has a market cap of 2.2B. Regarding current trading prices, ADMS is priced at $8.22, while PAHC trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PAHC's P/E ratio is 23.61. In terms of profitability, ADMS's ROE is +2.26%, compared to PAHC's ROE of +0.31%. Regarding short-term risk, ADMS is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check PAHC's competition here
ADMS vs AVDL Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ADMS is priced at $8.22, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ADMS's ROE is +2.26%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, ADMS is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check AVDL's competition here
ADMS vs EMBCV Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ADMS is priced at $8.22, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ADMS's ROE is +2.26%, compared to EMBCV's ROE of -0.28%. Regarding short-term risk, ADMS is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check EMBCV's competition here
ADMS vs BHC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, BHC has a market cap of 1.9B. Regarding current trading prices, ADMS is priced at $8.22, while BHC trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BHC's P/E ratio is 12.00. In terms of profitability, ADMS's ROE is +2.26%, compared to BHC's ROE of -0.20%. Regarding short-term risk, ADMS is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check BHC's competition here
ADMS vs DVAX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ADMS is priced at $8.22, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ADMS's ROE is +2.26%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, ADMS is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check DVAX's competition here
ADMS vs ANIP Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ADMS is priced at $8.22, while ANIP trades at $76.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ANIP's P/E ratio is 22.20. In terms of profitability, ADMS's ROE is +2.26%, compared to ANIP's ROE of +0.16%. Regarding short-term risk, ADMS is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ANIP's competition here
ADMS vs TARO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ADMS is priced at $8.22, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TARO's P/E ratio is 30.05. In terms of profitability, ADMS's ROE is +2.26%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ADMS is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check TARO's competition here
ADMS vs PRGO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, PRGO has a market cap of 1.3B. Regarding current trading prices, ADMS is priced at $8.22, while PRGO trades at $10.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PRGO's P/E ratio is -0.96. In terms of profitability, ADMS's ROE is +2.26%, compared to PRGO's ROE of -0.35%. Regarding short-term risk, ADMS is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check PRGO's competition here
ADMS vs HROW Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ADMS is priced at $8.22, while HROW trades at $35.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HROW's P/E ratio is -237.86. In terms of profitability, ADMS's ROE is +2.26%, compared to HROW's ROE of -0.10%. Regarding short-term risk, ADMS is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check HROW's competition here
ADMS vs ALVO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ALVO has a market cap of 1B. Regarding current trading prices, ADMS is priced at $8.22, while ALVO trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ALVO's P/E ratio is 32.90. In terms of profitability, ADMS's ROE is +2.26%, compared to ALVO's ROE of -0.26%. Regarding short-term risk, ADMS is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ALVO's competition here
ADMS vs COLL Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, COLL has a market cap of 1B. Regarding current trading prices, ADMS is priced at $8.22, while COLL trades at $32.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas COLL's P/E ratio is 18.49. In terms of profitability, ADMS's ROE is +2.26%, compared to COLL's ROE of +0.24%. Regarding short-term risk, ADMS is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check COLL's competition here
ADMS vs PCRX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, ADMS is priced at $8.22, while PCRX trades at $22.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PCRX's P/E ratio is 145.44. In terms of profitability, ADMS's ROE is +2.26%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, ADMS is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check PCRX's competition here
ADMS vs CRON Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, CRON has a market cap of 938.5M. Regarding current trading prices, ADMS is priced at $8.22, while CRON trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CRON's P/E ratio is -122.00. In terms of profitability, ADMS's ROE is +2.26%, compared to CRON's ROE of -0.01%. Regarding short-term risk, ADMS is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check CRON's competition here
ADMS vs PETQ Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ADMS is priced at $8.22, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ADMS's ROE is +2.26%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ADMS is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check PETQ's competition here
ADMS vs AMPH Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, AMPH has a market cap of 883.2M. Regarding current trading prices, ADMS is priced at $8.22, while AMPH trades at $19.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AMPH's P/E ratio is 9.47. In terms of profitability, ADMS's ROE is +2.26%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, ADMS is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check AMPH's competition here
ADMS vs EVO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EVO has a market cap of 838.8M. Regarding current trading prices, ADMS is priced at $8.22, while EVO trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EVO's P/E ratio is -4.54. In terms of profitability, ADMS's ROE is +2.26%, compared to EVO's ROE of -0.17%. Regarding short-term risk, ADMS is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check EVO's competition here
ADMS vs TLRY Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TLRY has a market cap of 606.5M. Regarding current trading prices, ADMS is priced at $8.22, while TLRY trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TLRY's P/E ratio is -0.25. In terms of profitability, ADMS's ROE is +2.26%, compared to TLRY's ROE of -1.14%. Regarding short-term risk, ADMS is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TLRY's competition here
ADMS vs BDSI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ADMS is priced at $8.22, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ADMS's ROE is +2.26%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ADMS is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check BDSI's competition here
ADMS vs ESPR Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ESPR has a market cap of 546.8M. Regarding current trading prices, ADMS is priced at $8.22, while ESPR trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ESPR's P/E ratio is -23.91. In terms of profitability, ADMS's ROE is +2.26%, compared to ESPR's ROE of +0.06%. Regarding short-term risk, ADMS is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ESPR's competition here
ADMS vs IRWD Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, IRWD has a market cap of 526.7M. Regarding current trading prices, ADMS is priced at $8.22, while IRWD trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas IRWD's P/E ratio is 21.53. In terms of profitability, ADMS's ROE is +2.26%, compared to IRWD's ROE of -0.08%. Regarding short-term risk, ADMS is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check IRWD's competition here
ADMS vs EMBC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EMBC has a market cap of 523.5M. Regarding current trading prices, ADMS is priced at $8.22, while EMBC trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EMBC's P/E ratio is 3.75. In terms of profitability, ADMS's ROE is +2.26%, compared to EMBC's ROE of -0.21%. Regarding short-term risk, ADMS is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check EMBC's competition here
ADMS vs KMDA Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, KMDA has a market cap of 465.5M. Regarding current trading prices, ADMS is priced at $8.22, while KMDA trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas KMDA's P/E ratio is 23.06. In terms of profitability, ADMS's ROE is +2.26%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ADMS is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check KMDA's competition here
ADMS vs EBS Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EBS has a market cap of 416.8M. Regarding current trading prices, ADMS is priced at $8.22, while EBS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EBS's P/E ratio is 8.66. In terms of profitability, ADMS's ROE is +2.26%, compared to EBS's ROE of +0.10%. Regarding short-term risk, ADMS is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check EBS's competition here
ADMS vs AQST Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, AQST has a market cap of 401.2M. Regarding current trading prices, ADMS is priced at $8.22, while AQST trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AQST's P/E ratio is -5.18. In terms of profitability, ADMS's ROE is +2.26%, compared to AQST's ROE of +1.96%. Regarding short-term risk, ADMS is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check AQST's competition here
ADMS vs CGC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, CGC has a market cap of 384.7M. Regarding current trading prices, ADMS is priced at $8.22, while CGC trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CGC's P/E ratio is -0.63. In terms of profitability, ADMS's ROE is +2.26%, compared to CGC's ROE of -0.53%. Regarding short-term risk, ADMS is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check CGC's competition here
ADMS vs SIGA Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SIGA has a market cap of 376.8M. Regarding current trading prices, ADMS is priced at $8.22, while SIGA trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SIGA's P/E ratio is 16.44. In terms of profitability, ADMS's ROE is +2.26%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, ADMS is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SIGA's competition here
ADMS vs SNDL Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SNDL has a market cap of 334.4M. Regarding current trading prices, ADMS is priced at $8.22, while SNDL trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SNDL's P/E ratio is -32.25. In terms of profitability, ADMS's ROE is +2.26%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, ADMS is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SNDL's competition here
ADMS vs ALIM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ADMS is priced at $8.22, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ADMS's ROE is +2.26%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ADMS is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check ALIM's competition here
ADMS vs ORGO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ORGO has a market cap of 294.6M. Regarding current trading prices, ADMS is priced at $8.22, while ORGO trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ORGO's P/E ratio is 15.27. In terms of profitability, ADMS's ROE is +2.26%, compared to ORGO's ROE of +0.10%. Regarding short-term risk, ADMS is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ORGO's competition here
ADMS vs LNDC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ADMS is priced at $8.22, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ADMS's ROE is +2.26%, compared to LNDC's ROE of -14.63%. Regarding short-term risk, ADMS is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check LNDC's competition here
ADMS vs EOLS Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EOLS has a market cap of 256.3M. Regarding current trading prices, ADMS is priced at $8.22, while EOLS trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EOLS's P/E ratio is -4.92. In terms of profitability, ADMS's ROE is +2.26%, compared to EOLS's ROE of +2.68%. Regarding short-term risk, ADMS is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check EOLS's competition here
ADMS vs TYHT Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ADMS is priced at $8.22, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ADMS's ROE is +2.26%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, ADMS is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TYHT's competition here
ADMS vs REPH Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ADMS is priced at $8.22, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas REPH's P/E ratio is -8.04. In terms of profitability, ADMS's ROE is +2.26%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ADMS is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check REPH's competition here
ADMS vs ACB Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ACB has a market cap of 174.7M. Regarding current trading prices, ADMS is priced at $8.22, while ACB trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ACB's P/E ratio is -2.85. In terms of profitability, ADMS's ROE is +2.26%, compared to ACB's ROE of -0.08%. Regarding short-term risk, ADMS is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ACB's competition here
ADMS vs OGI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, OGI has a market cap of 170.4M. Regarding current trading prices, ADMS is priced at $8.22, while OGI trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas OGI's P/E ratio is 11.36. In terms of profitability, ADMS's ROE is +2.26%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ADMS is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check OGI's competition here
ADMS vs THTX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ADMS is priced at $8.22, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas THTX's P/E ratio is -17.84. In terms of profitability, ADMS's ROE is +2.26%, compared to THTX's ROE of +0.47%. Regarding short-term risk, ADMS is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check THTX's competition here
ADMS vs TKNO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TKNO has a market cap of 143.6M. Regarding current trading prices, ADMS is priced at $8.22, while TKNO trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TKNO's P/E ratio is -8.37. In terms of profitability, ADMS's ROE is +2.26%, compared to TKNO's ROE of -0.23%. Regarding short-term risk, ADMS is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TKNO's competition here
ADMS vs LFCR Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, LFCR has a market cap of 142M. Regarding current trading prices, ADMS is priced at $8.22, while LFCR trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LFCR's P/E ratio is -2.98. In terms of profitability, ADMS's ROE is +2.26%, compared to LFCR's ROE of -1.82%. Regarding short-term risk, ADMS is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check LFCR's competition here
ADMS vs CRDL Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, CRDL has a market cap of 136.2M. Regarding current trading prices, ADMS is priced at $8.22, while CRDL trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CRDL's P/E ratio is -4.07. In terms of profitability, ADMS's ROE is +2.26%, compared to CRDL's ROE of -2.03%. Regarding short-term risk, ADMS is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check CRDL's competition here
ADMS vs ASRT Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ASRT has a market cap of 117.8M. Regarding current trading prices, ADMS is priced at $8.22, while ASRT trades at $19.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ASRT's P/E ratio is -57.12. In terms of profitability, ADMS's ROE is +2.26%, compared to ASRT's ROE of -0.29%. Regarding short-term risk, ADMS is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ASRT's competition here
ADMS vs SCTL Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ADMS is priced at $8.22, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ADMS's ROE is +2.26%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ADMS is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SCTL's competition here
ADMS vs DERM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, DERM has a market cap of 107.5M. Regarding current trading prices, ADMS is priced at $8.22, while DERM trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DERM's P/E ratio is -9.34. In terms of profitability, ADMS's ROE is +2.26%, compared to DERM's ROE of -0.46%. Regarding short-term risk, ADMS is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check DERM's competition here
ADMS vs PROC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ADMS is priced at $8.22, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PROC's P/E ratio is 1.53. In terms of profitability, ADMS's ROE is +2.26%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ADMS is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check PROC's competition here
ADMS vs OPTN Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ADMS is priced at $8.22, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ADMS's ROE is +2.26%, compared to OPTN's ROE of +0.47%. Regarding short-term risk, ADMS is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check OPTN's competition here
ADMS vs ALVOW Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ALVOW has a market cap of 96.8M. Regarding current trading prices, ADMS is priced at $8.22, while ALVOW trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ADMS's ROE is +2.26%, compared to ALVOW's ROE of -0.26%. Regarding short-term risk, ADMS is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check ALVOW's competition here
ADMS vs ZOM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ADMS is priced at $8.22, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ADMS's ROE is +2.26%, compared to ZOM's ROE of -0.66%. Regarding short-term risk, ADMS is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ZOM's competition here
ADMS vs BGM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, BGM has a market cap of 89.2M. Regarding current trading prices, ADMS is priced at $8.22, while BGM trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BGM's P/E ratio is -1.53. In terms of profitability, ADMS's ROE is +2.26%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ADMS is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check BGM's competition here
ADMS vs GRVI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ADMS is priced at $8.22, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ADMS's ROE is +2.26%, compared to GRVI's ROE of -1.20%. Regarding short-term risk, ADMS is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check GRVI's competition here
ADMS vs ZYNE Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ADMS is priced at $8.22, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ADMS's ROE is +2.26%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ADMS is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ZYNE's competition here
ADMS vs SSIC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ADMS is priced at $8.22, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ADMS's ROE is +2.26%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ADMS is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SSIC's competition here
ADMS vs VLNS Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ADMS is priced at $8.22, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ADMS's ROE is +2.26%, compared to VLNS's ROE of N/A. Regarding short-term risk, ADMS is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check VLNS's competition here
ADMS vs DRRX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ADMS is priced at $8.22, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ADMS's ROE is +2.26%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, ADMS is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check DRRX's competition here
ADMS vs JUPW Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ADMS is priced at $8.22, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ADMS's ROE is +2.26%, compared to JUPW's ROE of -0.99%. Regarding short-term risk, ADMS is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check JUPW's competition here
ADMS vs CPIX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, CPIX has a market cap of 46.7M. Regarding current trading prices, ADMS is priced at $8.22, while CPIX trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CPIX's P/E ratio is -16.42. In terms of profitability, ADMS's ROE is +2.26%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, ADMS is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check CPIX's competition here
ADMS vs INCR Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, INCR has a market cap of 40.1M. Regarding current trading prices, ADMS is priced at $8.22, while INCR trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas INCR's P/E ratio is -1.50. In terms of profitability, ADMS's ROE is +2.26%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ADMS is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check INCR's competition here
ADMS vs ZYBT Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ZYBT has a market cap of 39M. Regarding current trading prices, ADMS is priced at $8.22, while ZYBT trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZYBT's P/E ratio is -13.71. In terms of profitability, ADMS's ROE is +2.26%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, ADMS is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ZYBT's competition here
ADMS vs QLI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ADMS is priced at $8.22, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas QLI's P/E ratio is -4.92. In terms of profitability, ADMS's ROE is +2.26%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ADMS is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check QLI's competition here
ADMS vs SCYX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SCYX has a market cap of 35.3M. Regarding current trading prices, ADMS is priced at $8.22, while SCYX trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -4.65. In terms of profitability, ADMS's ROE is +2.26%, compared to SCYX's ROE of -0.19%. Regarding short-term risk, ADMS is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SCYX's competition here
ADMS vs IXHL Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, IXHL has a market cap of 34.9M. Regarding current trading prices, ADMS is priced at $8.22, while IXHL trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas IXHL's P/E ratio is -0.14. In terms of profitability, ADMS's ROE is +2.26%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, ADMS is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check IXHL's competition here
ADMS vs RMTI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, RMTI has a market cap of 33.5M. Regarding current trading prices, ADMS is priced at $8.22, while RMTI trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas RMTI's P/E ratio is -5.67. In terms of profitability, ADMS's ROE is +2.26%, compared to RMTI's ROE of -156.37%. Regarding short-term risk, ADMS is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check RMTI's competition here
ADMS vs HEXO Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ADMS is priced at $8.22, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ADMS's ROE is +2.26%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ADMS is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check HEXO's competition here
ADMS vs CYTH Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ADMS is priced at $8.22, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ADMS's ROE is +2.26%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ADMS is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check CYTH's competition here
ADMS vs TXMD Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TXMD has a market cap of 23M. Regarding current trading prices, ADMS is priced at $8.22, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TXMD's P/E ratio is 199.00. In terms of profitability, ADMS's ROE is +2.26%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, ADMS is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TXMD's competition here
ADMS vs AYTU Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, AYTU has a market cap of 21.2M. Regarding current trading prices, ADMS is priced at $8.22, while AYTU trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AYTU's P/E ratio is -0.76. In terms of profitability, ADMS's ROE is +2.26%, compared to AYTU's ROE of -1.07%. Regarding short-term risk, ADMS is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check AYTU's competition here
ADMS vs EVOK Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ADMS is priced at $8.22, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ADMS's ROE is +2.26%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, ADMS is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check EVOK's competition here
ADMS vs QNTM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, QNTM has a market cap of 17.3M. Regarding current trading prices, ADMS is priced at $8.22, while QNTM trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas QNTM's P/E ratio is -0.51. In terms of profitability, ADMS's ROE is +2.26%, compared to QNTM's ROE of -4.19%. Regarding short-term risk, ADMS is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check QNTM's competition here
ADMS vs TLPH Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, TLPH has a market cap of 15.3M. Regarding current trading prices, ADMS is priced at $8.22, while TLPH trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TLPH's P/E ratio is -2.19. In terms of profitability, ADMS's ROE is +2.26%, compared to TLPH's ROE of -1.18%. Regarding short-term risk, ADMS is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check TLPH's competition here
ADMS vs ACRX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ADMS is priced at $8.22, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ADMS's ROE is +2.26%, compared to ACRX's ROE of -1.18%. Regarding short-term risk, ADMS is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ACRX's competition here
ADMS vs AGRX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ADMS is priced at $8.22, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ADMS's ROE is +2.26%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ADMS is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check AGRX's competition here
ADMS vs BFRI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, BFRI has a market cap of 9.1M. Regarding current trading prices, ADMS is priced at $8.22, while BFRI trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -0.75. In terms of profitability, ADMS's ROE is +2.26%, compared to BFRI's ROE of -11.39%. Regarding short-term risk, ADMS is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check BFRI's competition here
ADMS vs COSM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, COSM has a market cap of 8.9M. Regarding current trading prices, ADMS is priced at $8.22, while COSM trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.42. In terms of profitability, ADMS's ROE is +2.26%, compared to COSM's ROE of -0.74%. Regarding short-term risk, ADMS is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check COSM's competition here
ADMS vs NLTX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ADMS is priced at $8.22, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ADMS's ROE is +2.26%, compared to NLTX's ROE of -0.33%. Regarding short-term risk, ADMS is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check NLTX's competition here
ADMS vs LCI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ADMS is priced at $8.22, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LCI's P/E ratio is -0.04. In terms of profitability, ADMS's ROE is +2.26%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ADMS is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check LCI's competition here
ADMS vs BGXX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ADMS is priced at $8.22, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ADMS's ROE is +2.26%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, ADMS is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check BGXX's competition here
ADMS vs ADMP Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ADMS is priced at $8.22, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ADMS's ROE is +2.26%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ADMS is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check ADMP's competition here
ADMS vs YCBD Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, YCBD has a market cap of 6.8M. Regarding current trading prices, ADMS is priced at $8.22, while YCBD trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas YCBD's P/E ratio is 1.08. In terms of profitability, ADMS's ROE is +2.26%, compared to YCBD's ROE of -0.41%. Regarding short-term risk, ADMS is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check YCBD's competition here
ADMS vs GELS Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, GELS has a market cap of 6.8M. Regarding current trading prices, ADMS is priced at $8.22, while GELS trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas GELS's P/E ratio is -1.48. In terms of profitability, ADMS's ROE is +2.26%, compared to GELS's ROE of -0.43%. Regarding short-term risk, ADMS is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check GELS's competition here
ADMS vs SBFM Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, SBFM has a market cap of 5M. Regarding current trading prices, ADMS is priced at $8.22, while SBFM trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SBFM's P/E ratio is 0.19. In terms of profitability, ADMS's ROE is +2.26%, compared to SBFM's ROE of -0.25%. Regarding short-term risk, ADMS is less volatile compared to SBFM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check SBFM's competition here
ADMS vs MNK Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ADMS is priced at $8.22, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas MNK's P/E ratio is -0.44. In terms of profitability, ADMS's ROE is +2.26%, compared to MNK's ROE of +0.11%. Regarding short-term risk, ADMS is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check MNK's competition here
ADMS vs EGRX Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, EGRX has a market cap of 4.4M. Regarding current trading prices, ADMS is priced at $8.22, while EGRX trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EGRX's P/E ratio is 4.87. In terms of profitability, ADMS's ROE is +2.26%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ADMS is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check EGRX's competition here
ADMS vs FLGC Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ADMS is priced at $8.22, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ADMS's ROE is +2.26%, compared to FLGC's ROE of -0.12%. Regarding short-term risk, ADMS is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.Check FLGC's competition here
ADMS vs GHSI Comparison April 2026
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at 0. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, ADMS is priced at $8.22, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas GHSI's P/E ratio is -0.79. In terms of profitability, ADMS's ROE is +2.26%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, ADMS is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.Check GHSI's competition here